Key statistics
On Friday, Castle Biosciences Inc (CSTL:NMQ) closed at 33.15, -25.14% below its 52-week high of 44.28, set on Jan 26, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 31.84 |
|---|---|
| High | 33.66 |
| Low | 31.84 |
| Bid | 29.75 |
| Offer | 46.00 |
| Previous close | 31.90 |
| Average volume | 444.62k |
|---|---|
| Shares outstanding | 29.19m |
| Free float | 28.34m |
| P/E (TTM) | -- |
| Market cap | 967.60m USD |
| EPS (TTM) | -0.4533 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
- Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
- Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
- Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
- Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
- New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
- Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
- Castle Biosciences Reports Third Quarter 2025 Results
More ▼
